Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques - PubMed (original) (raw)
Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques
G Franchini et al. AIDS Res Hum Retroviruses. 1995 Aug.
Abstract
Immunization schemes employing priming with vector-based vaccine candidates followed by subunit booster administrations have been explored and shown to have merit in the human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus systems. In this study, we have assessed the priming capacity of highly attenuated poxvirus vector (NYVAC and ALVAC)-based HIV-2 recombinants, as well as Salmonella typhimurium HIV-2 recombinants in rhesus macaques. ALVAC- and NYVAC-based vaccine candidates expressing the HIV-2 gag, pol, and env genes or NYVAC-based recombinants expressing either gp160 or gp120 were used to immunize rhesus macaques in combination protocols with alum-adjuvanted HIV-2 rgp160. Following intravenous challenge exposure with 100 infectious doses of the HIV-2SBL6669 parental virus genotype mixture, seven of eight animals were protected from infection. The seven protected animals were rechallenged 6 months postprimary challenge, without additional booster inoculations, with the same dose of the HIV-2SBL6669 parental virus. Five of the seven animals remained protected against HIV-2 infection at 6 months following the second challenge. In contrast, oral immunization with recombinant Salmonella expressing the HIV-2 gag and the gp120 portion of the envelope either alone or in combination with alum-adjuvanted rgp160 failed to confer protection. These results suggest that the NYVAC- and ALVAC-based recombinants may confer long-lasting protection and that these two highly attenuated poxvirus vaccine vectors may represent promising candidates for developing an acquired immunodeficiency syndrome vaccine.
Similar articles
- Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques.
Myagkikh M, Alipanah S, Markham PD, Tartaglia J, Paoletti E, Gallo RC, Franchini G, Robert-Guroff M. Myagkikh M, et al. AIDS Res Hum Retroviruses. 1996 Jul 20;12(11):985-92. doi: 10.1089/aid.1996.12.985. AIDS Res Hum Retroviruses. 1996. PMID: 8827214 - Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.
García-Arriaza J, Perdiguero B, Heeney J, Seaman M, Montefiori DC, Labranche C, Yates NL, Shen X, Tomaras GD, Ferrari G, Foulds KE, McDermott A, Kao SF, Roederer M, Hawkins N, Self S, Yao J, Farrell P, Phogat S, Tartaglia J, Barnett SW, Burke B, Cristillo A, Weiss D, Lee C, Kibler K, Jacobs B, Asbach B, Wagner R, Ding S, Pantaleo G, Esteban M. García-Arriaza J, et al. J Virol. 2015 Aug;89(16):8525-39. doi: 10.1128/JVI.01265-15. Epub 2015 Jun 3. J Virol. 2015. PMID: 26041302 Free PMC article. - Cross-protection in NYVAC-HIV-1-immunized/HIV-2-challenged but not in NYVAC-HIV-2-immunized/SHIV-challenged rhesus macaques.
Patterson LJ, Peng B, Abimiku AG, Aldrich K, Murty L, Markham PD, Kalyanaraman VS, Alvord WG, Tartaglia J, Franchini G, Robert-Guroff M. Patterson LJ, et al. AIDS. 2000 Nov 10;14(16):2445-55. doi: 10.1097/00002030-200011100-00005. AIDS. 2000. PMID: 11101054 - Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC.
Paoletti E, Taylor J, Meignier B, Meric C, Tartaglia J. Paoletti E, et al. Dev Biol Stand. 1995;84:159-63. Dev Biol Stand. 1995. PMID: 7796949 Review. - Enhancing poxvirus vectors vaccine immunogenicity.
García-Arriaza J, Esteban M. García-Arriaza J, et al. Hum Vaccin Immunother. 2014;10(8):2235-44. doi: 10.4161/hv.28974. Hum Vaccin Immunother. 2014. PMID: 25424927 Free PMC article. Review.
Cited by
- Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisition.
Gorini G, Fourati S, Vaccari M, Rahman MA, Gordon SN, Brown DR, Law L, Chang J, Green R, Barrenäs F, Liyanage NPM, Doster MN, Schifanella L, Bissa M, Silva de Castro I, Washington-Parks R, Galli V, Fuller DH, Santra S, Agy M, Pal R, Palermo RE, Tomaras GD, Shen X, LaBranche CC, Montefiori DC, Venzon DJ, Trinh HV, Rao M, Gale M Jr, Sekaly RP, Franchini G. Gorini G, et al. PLoS Pathog. 2020 Mar 12;16(3):e1008377. doi: 10.1371/journal.ppat.1008377. eCollection 2020 Mar. PLoS Pathog. 2020. PMID: 32163525 Free PMC article. - Viral Vectors for the Induction of Broadly Neutralizing Antibodies against HIV.
Wilmschen S, Schmitz JE, Kimpel J. Wilmschen S, et al. Vaccines (Basel). 2019 Sep 19;7(3):119. doi: 10.3390/vaccines7030119. Vaccines (Basel). 2019. PMID: 31546894 Free PMC article. Review. - Mucosal Vaccine Approaches for Prevention of HIV and SIV Transmission.
Kozlowski PA, Aldovini A. Kozlowski PA, et al. Curr Immunol Rev. 2019;15(1):102-122. doi: 10.2174/1573395514666180605092054. Curr Immunol Rev. 2019. PMID: 31452652 Free PMC article. - Antibody to the gp120 V1/V2 loops and CD4+ and CD8+ T cell responses in protection from SIVmac251 vaginal acquisition and persistent viremia.
Gordon SN, Doster MN, Kines RC, Keele BF, Brocca-Cofano E, Guan Y, Pegu P, Liyanage NP, Vaccari M, Cuburu N, Buck CB, Ferrari G, Montefiori D, Piatak M Jr, Lifson JD, Xenophontos AM, Venzon D, Robert-Guroff M, Graham BS, Lowy DR, Schiller JT, Franchini G. Gordon SN, et al. J Immunol. 2014 Dec 15;193(12):6172-83. doi: 10.4049/jimmunol.1401504. Epub 2014 Nov 14. J Immunol. 2014. PMID: 25398324 Free PMC article. - Induction of intestinal immunity by mucosal vaccines as a means of controlling HIV infection.
Poles J, Alvarez Y, Hioe CE. Poles J, et al. AIDS Res Hum Retroviruses. 2014 Nov;30(11):1027-40. doi: 10.1089/aid.2014.0233. AIDS Res Hum Retroviruses. 2014. PMID: 25354023 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical